November 24, 2025 Oral PCSK9 Inhibitor Tied to LDL-C Drop The oral PCSK9 inhibitor enlicitide decanoate achieved 58% LDL-C reduction in patients with heterozygous familial hypercholesterolemia, offering a potential alternative to injectable therapies. Conexiant